Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of phase 3 duloxetine trial in pediatric depressive disorder
jRCT2080223797Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of duloxetine in major depressive disorder (MDD) and persistent depressive disorder (PDD) (2 arms), sponsored by Shionogi & Co., Ltd. Started Feb 2018; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on jRCT2080223797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223797.